Atorvastatin Restores PPARα Inhibition of Lipid Metabolism Disorders by Downregulating miR-21 Expression to Improve Mitochondrial Function and Alleviate Diabetic Nephropathy Progression

• Main Authors: Jiayi Xiang (Author), Huifang Zhang (Author), Xingcheng Zhou (Author), Dan Wang (Author), Rongyu Chen (Author), Wanlin Tan (Author), Luqun Liang (Author), Mingjun Shi (Author), Fan Zhang (Author), Ying Xiao (Author), Yuxia Zhou (Author), Yuanyuan Wang (Author), Bing Guo (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Atorvastatin is a classical lipid-lowering drug. It has been reported to have renoprotective effects, such as reducing urinary protein excretion and extracellular matrix aggregation. The present study aimed to investigate the specific mechanism of action of Atorvastatin in type 1 diabetic mice (T1DM...